[Robert: paste actual Google Review quote — filtered to mention this page's topic]
[Robert: First name + initial]
[Robert: month year of review]
Two of the world's most-prescribed weight-loss medications, head-to-head. Tirzepatide (Mounjaro and Zepbound, Eli Lilly) is a dual GIP and GLP-1 receptor agonist that delivered 20.9 percent body-weight loss at 72 weeks in SURMOUNT-1. Semaglutide (Wegovy, Novo Nordisk) is a single GLP-1 agonist that delivered 14.9 percent at 68 weeks in STEP-1. The 2025 SURMOUNT-5 direct-comparison trial confirmed tirzepatide's 6.5-percentage-point advantage.
Treatments supervised by Dr. Kenika Norrachetdecha
Medical Director · Thai License #72509
● Mon–Sat 8 AM–6 PM · Online consults daily · Reply in 2 Min
Personal consultation included with every program
That's −17.8 kg — you'd weigh .
Based on the 20.9% trial-mean. Individual outcomes vary.Both medications are doctor-led, FDA-tracked, and available through licensed Thai clinics. The right choice depends on your goal, history, and tolerance.
Not sure? Dr. Kenika reviews your medical history in a 30-minute consultation and recommends the right molecule for your case.
Tirzepatide and semaglutide are both gut-hormone receptor agonists, but they target different combinations of receptors. The difference explains why the head-to-head trial outcomes diverge.
Wegovy and Ozempic activate the GLP-1 receptor alone. GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after meals — it signals fullness, slows gastric emptying, and stimulates insulin release. Semaglutide binds to this single receptor with high affinity and produces sustained GLP-1 effects throughout the week (it's a weekly injection because of its 7-day half-life).
Mounjaro and Zepbound activate two receptors: GLP-1 AND GIP (glucose-dependent insulinotropic polypeptide). GIP is a separate gut hormone that complements GLP-1 — it enhances insulin secretion, affects fat-cell metabolism, and may improve sensitivity to GLP-1 effects in the brain. The dual activation produces additional metabolic effects that single-receptor semaglutide cannot match.
SURMOUNT-1 (tirzepatide 15 mg, 72 weeks) achieved a 20.9% mean body-weight reduction. STEP-1 (semaglutide 2.4 mg, 68 weeks) achieved 14.9%. The 6-percentage-point gap was confirmed in the direct head-to-head SURMOUNT-5 trial published in NEJM in 2025 — tirzepatide 20.2% versus semaglutide 13.7% at 72 weeks.
For patients targeting maximum weight loss, the mechanism difference matters. For patients targeting cardiovascular protection or those with established CV disease, semaglutide remains the evidence-leader — the SELECT trial (2023) demonstrated 20% reduction in major adverse cardiovascular events over 5 years of semaglutide therapy.
Both medications were tested in large Phase 3 randomized controlled trials published in the New England Journal of Medicine. Here is the full comparison.
The SURMOUNT-5 trial (NEJM, May 2025) randomized adults with obesity to tirzepatide 15 mg vs semaglutide 2.4 mg over 72 weeks. Result: tirzepatide delivered 20.2% body-weight loss vs 13.7% for semaglutide — a 6.5-percentage-point absolute advantage consistent with the indirect comparison above.
Pricing reflects authentic, prescription-channel medication with doctor consultation and ongoing monitoring included. Hospital pricing (Bumrungrad, Samitivej, BNH) ranges 18,000–30,000 THB per month for the same medication.
Cost difference is minimal (~5%). Choose by clinical fit, not by price. Both are 40–60% below hospital pricing at TRT Bangkok.
Pick your treatment, enter your weights, see your trajectory. All data from peer-reviewed clinical trials. Individual outcomes vary — final program plan determined in private consultation.
Your trajectory · based on clinical-trial mean
Trial data: SURMOUNT-1 (Jastreboff AM et al, NEJM 2022;387:205-216) and STEP-1 (Wilding JPH et al, NEJM 2021;384:989-1002). Head-to-head data: SURMOUNT-5 (NEJM 2025) showed tirzepatide 15 mg delivered 20.2 percent vs semaglutide 2.4 mg delivered 13.7 percent at 72 weeks. Real-world outcomes depend on dose-titration tolerance, lifestyle, and adherence. Dr. Kenika determines fit during your private consultation.
Each program is personalized based on your profile, medical history, and goals.
Step 1 of 5
Step 2 of 5
Select all that apply, or "None of these"
Step 3 of 5
Confidential — only your doctor sees this
Step 4 of 5
Step 5 of 5
Dr. Kenika's recommendation for you
Your access
—
Our actual clinic · Real photos
Authentic medications. Direct access to Dr. Kenika. Comprehensive metabolic care beyond GLP-1 alone.
Authentic Medications
Mounjaro, Zepbound (Eli Lilly), Wegovy, Ozempic, Saxenda (Novo Nordisk) — all sourced through the licensed Thai pharmaceutical supply chain.
Direct Doctor Access
WhatsApp Dr. Kenika directly. Every GLP-1 prescription personally supervised by the Medical Director.
Beyond GLP-1
Multi-modal metabolic care: GLP-1 plus hormone optimization, IV recovery, and advanced peptide protocols.
In Thailand for treatment? Want to discuss your Mounjaro vs Wegovy decision in person? Visit our Pattaya location — walk-in welcome, English-speaking medical team.
Tirzepatide (Mounjaro / Zepbound) at 15 mg: 20.9% mean body-weight loss at 72 weeks (SURMOUNT-1). Semaglutide 2.4 mg (Wegovy): 14.9% at 68 weeks (STEP-1). Tirzepatide delivers ~40% more weight loss on average.
Tirzepatide is a DUAL agonist — it activates both GLP-1 and GIP receptors. Semaglutide is a SINGLE GLP-1 agonist. The dual mechanism explains tirzepatide's superior efficacy in head-to-head comparisons.
Wegovy (semaglutide 2.4 mg) — FDA-approved for chronic weight management plus cardiovascular risk reduction. Zepbound (tirzepatide) — FDA-approved for obesity + comorbidity. Mounjaro is FDA-approved for type 2 diabetes only; weight-loss use is off-label.
Mounjaro / Zepbound: from ฿2,190 per shot or ฿16,990/month for take-home pen. Wegovy / Ozempic: from ฿1,990 per shot. Pricing is similar — choice should be clinical fit, not cost difference.
Both share nausea, diarrhea, vomiting (most pronounced during dose-escalation, weeks 4–8). Tirzepatide may show slightly higher GI rates due to dual mechanism. Both carry boxed warning for medullary thyroid carcinoma (MTC) and contraindication in MEN-2 syndrome.
Tirzepatide if you target maximum weight-loss (20%+) or have type 2 diabetes. Semaglutide if you have established cardiovascular disease (SELECT trial CV benefit) or prefer the longer real-world safety track-record. Dr. Kenika reviews medical history during consultation.
Yes. Switching is possible after appropriate washout (1–2 weeks). Some patients start on semaglutide and transition to tirzepatide if more weight loss is needed. Dose-titration restart is required.
The SURMOUNT-5 trial directly compared tirzepatide 15 mg vs semaglutide 2.4 mg in adults with obesity. Tirzepatide produced 20.2% weight loss vs 13.7% for semaglutide at 72 weeks — a 6.5 percentage-point absolute advantage (NEJM 2025).
Licensed
Thai Pharmacy
Pharmaceutical
Grade
Doctor
Supervised
Same-Day
Care
Real reviews from real patients on Google Business Profile. Currently 5.0 ★ from 15 verified reviews — and growing. Reviews are updated regularly.
[Robert: paste actual Google Review quote — filtered to mention this page's topic]
[Robert: paste actual Google Review quote — filtered to mention this page's topic]
[Robert: paste actual Google Review quote — filtered to mention this page's topic]
Peer-reviewed primary sources, FDA prescribing information, and manufacturer documentation.
Additional clinical questions are discussed during your private consultation with Dr. Kenika.
Direct access to Dr. Kenika. Authentic medications. Three access points across Thailand.
Personal medical supervision · Cancel anytime · Authentic medications from Eli Lilly and Novo Nordisk
Book via WhatsApp · Free eligibility check
Each GLP-1 protocol has a different mechanism, trial profile, and outcome ceiling. Compare or explore by location.
Eli Lilly's dual GIP/GLP-1 agonist. Highest trial-mean of any approved GLP-1. Best fit for goals above 15%.
See program →
Novo Nordisk's most-prescribed GLP-1. Excellent track record for goals up to 15%. Built-in outcome estimator.
See program →
Investigational GLP-1/GIP/Glucagon triple agonist. Highest documented mean reduction. Private-consultation program.
See program →
In-person consultation, baseline labs, and same-week start. Walk-in or appointment. Most international patients begin here.
See clinic →